60 Degrees Pharmaceuticals Files 8-K
Ticker: SXTPW · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1946563
| Field | Detail |
|---|---|
| Company | 60 Degrees Pharmaceuticals, Inc. (SXTPW) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $1.021, $0.771, $15,000, $10,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
60 Degrees Pharma dropped an 8-K on Jan 28th - material agreement, equity sales, and more.
AI Summary
On January 28, 2025, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and potential financial events for 60 Degrees Pharmaceuticals, Inc., requiring investor attention.
Risk Assessment
Risk Level: medium — 8-K filings often signal material events that can impact stock price, but the specific nature of the agreement and sales requires further analysis.
Key Players & Entities
- 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- 001-41719 (company) — SEC File Number
- 45-2406880 (company) — IRS Employer Identification Number
FAQ
What is the nature of the material definitive agreement entered into by 60 Degrees Pharmaceuticals, Inc. on January 28, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by 60 Degrees Pharmaceuticals, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type of securities is not detailed in the provided text.
What are the key items reported under 'Other Events' in this 8-K filing?
The filing lists 'Other Events' as an item information category, but the specific events are not detailed in the provided text.
Where is 60 Degrees Pharmaceuticals, Inc. incorporated and what is its fiscal year end?
60 Degrees Pharmaceuticals, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
What is the business address and phone number for 60 Degrees Pharmaceuticals, Inc.?
The business address is 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON, DC 20036, and the phone number is 202-327-5422.
Filing Stats: 1,451 words · 6 min read · ~5 pages · Grade level 11 · Accepted 2025-01-30 17:30:25
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
- $1.021 — ("Common Stock") at a purchase price of $1.021 per share in a registered direct offeri
- $0.771 — of Common Stock at an exercise price of $0.771 per share. The Warrants are exercisable
- $15,000 — n-accountable expenses in the amount of $15,000 and a clearing fee in the amount of $10
- $10,000 — 000 and a clearing fee in the amount of $10,000. The Company also issued to the Placeme
- $1.2763 — arrants have an exercise price equal to $1.2763 per share and are exercisable upon issu
- $804,346.40 — received net proceeds of approximately $804,346.40 from the offering, after deducting esti
Filing Documents
- ea0229310-8k_60degrees.htm (8-K) — 56KB
- ea022931001ex1-1_60degrees.htm (EX-1.1) — 54KB
- ea022931001ex1-2_60degrees.htm (EX-1.2) — 12KB
- ea022931001ex1-3_60degrees.htm (EX-1.3) — 12KB
- ea022931001ex4-1_60degrees.htm (EX-4.1) — 94KB
- ea022931001ex4-2_60degrees.htm (EX-4.2) — 93KB
- ea022931001ex5-1_60degrees.htm (EX-5.1) — 11KB
- ea022931001ex10-1_60degrees.htm (EX-10.1) — 248KB
- ea022931001ex99-1_60degrees.htm (EX-99.1) — 13KB
- ea022931001ex99-2_60degrees.htm (EX-99.2) — 13KB
- ex5-1_001.jpg (GRAPHIC) — 24KB
- ex1-1_001.jpg (GRAPHIC) — 25KB
- ex1-2_001.jpg (GRAPHIC) — 25KB
- ex1-3_001.jpg (GRAPHIC) — 25KB
- 0001213900-25-008463.txt ( ) — 1111KB
- sxtp-20250128.xsd (EX-101.SCH) — 4KB
- sxtp-20250128_def.xml (EX-101.DEF) — 26KB
- sxtp-20250128_lab.xml (EX-101.LAB) — 36KB
- sxtp-20250128_pre.xml (EX-101.PRE) — 25KB
- ea0229310-8k_60degrees_htm.xml (XML) — 6KB
01
Item 8.01. Other Events. On January 29, 2025, the Company issued a press release announcing the pricing of the offering. A copy of the press release announcing this matter is filed as Exhibit 99.1 to this Report and is incorporated by reference into this Item 8.01. On January 30, 2025, the Company issued a press release announcing the closing of the offering. A copy of the press release announcing this matter is filed as Exhibit 99.2 to this Report and is incorporated by reference into this Item 8.01.
01
Item 9.01. Exhibits. (d) Exhibits Exhibit No. Description 1.1 Engagement Agreement 1.2 Amendment to Engagement Agreement 1.3 Extension to Engagement Agreement 4.1 Form of Warrant 4.2 Form of Placement Agent Warrant 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 10.1 Form of Securities Purchase Agreement 23.1 Consent of Sichenzia Ross Ference Carmel LLP (contained in Exhibit 5.1) 99.1 Press Release, dated January 29, 2025 99.2 Press Release, dated January 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: January 30, 2025 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 3